Die EvidentIQ Germany GmbH – Teil der EvidentIQ Group und führender Anbieter von EDC-Software (Electronic Data Capture) für klinische Studien – ist ab sofort Mitglied im Bundesverband Medizinischer Auftragsinstitute e.V. (BVMA). Mit der Mitgliedschaft im BVMA stärkt EvidentIQ Germany seine Position als verlässlicher Partner in der klinischen Forschung und unterstreicht sein Engagement für höchste Qualitäts- […]
continue reading
EvidentIQ Germany GmbH confirmed as a Platinum Pharma Supplier
EvidentIQ Germany was recognized as a Platinum Pharma Supplier by Qualifyze’s quality compliance program. This prestigious distinction acknowledges EvidentIQ Germany’s commitment to providing high-quality products and reliable services to the healthcare and pharmaceutical industries. Receiving the Platinum Quality Compliance Certificate reflects EvidentIQ Germany’s dedication to excellence and reinforces its role as a trusted partner in […]
continue reading
10 Years of Successful Partnership between EvidentIQ Germany and Cardialysis in the Field of Clinical Studies
EvidentIQ Germany, formerly known as XClinical, a top provider of EDC software, is proud to mark a decade of fruitful collaboration with Cardialysis, a renowned CRO & Core Laboratory based in the Netherlands. For the past ten years, EvidentIQ Germany and Cardialysis have joined forces to achieve impressive accomplishments in clinical research. Together, they have […]
continue reading
EvidentIQ is pleased to announce the addition of Asthenis GmbH to their comprehensive eClinical solutions group.
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of Asthenis GmbH, the market leader in cancer documentation software in the DACH region (Germany, Austria and Switzerland). EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, […]
continue reading
EvidentIQ Announces Change of Leadership
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, proudly announces a strategic leadership restructuring, setting the stage for the company’s continued growth and commitment to delivering unparalleled results for its clients. After three highly successful years of guiding EvidentIQ’s evolution and establishing it as a formidable player in the healthcare industry, […]
continue reading
Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies
EvidentIQ, the innovative provider of advanced clinical trial management solutions has joined forces with Quinta Analytica, a renowned GCP/GLP/GMP-certified European CRO and part of the Conscio Group. This collaboration aims to enhance the efficiency and effectiveness of data collection processes for Phase 1 studies, utilizing EvidentIQ’s Clindex eClinical system. According to Dr. Renata Vyhnálková, Quality […]
continue reading
Carenity, part of the EvidentIQ Group, announces change in leadership
Michael Chekroun, founder of Carenity and outgoing President, will be stepping down from his role as of today. Lise Radoszycki, former COO, will be taking the helm as the new President, bringing extensive experience and expertise that will propel the company into its next phase of expansion and development. Michael Chekroun has played for the […]
continue reading
Managed Service Model for OpenStudyBuilder
EvidentIQ launches a new Managed Service Model that not only supports the use of the open-source solution OpenStudyBuilder, but also helps clients customizing it to their specific requirements. Last year EvidentIQ released alongside Novo Nordisk, Neo4j, and Microsoft, a new solution for managing clinical data standards and study design specifications, the OpenStudyBuilder. In the world […]
continue reading
E2B Mailer: Safety Notifications Made Easy
EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system. EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse drug reactions (ADRs) outside of the scope of a full PV system in a trial […]
continue reading
EvidentIQ and Keyrus Life Science are building a strategic partnership
Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the Connected Contract Research Organization (C²RO), announced the signing of their partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities. EvidentIQ, based in Hamburg, is a leading clinical data science group, offering […]
continue reading